{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"34"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"580"},{"groupId":"OG001","value":"581"}],"units":"Participants"}],"description":"An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. The number of participants who discontinued study treatment due to an AE were reported.","groups":[{"description":"Participants received pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year.","id":"OG000","title":"Pembrolizumab"},{"description":"Participants received placebo, IV, every 3 weeks, for one year.","id":"OG001","title":"Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to approximately 19 months","title":"Number of Participants Who Discontinued Study Treatment Due to an AE","type":"SECONDARY","unitOfMeasure":"Participants"}